Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Feb 06 2026

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 4 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited announced that it has received Orphan Drug Designation from the USFDA for Desidustat, aimed at treating Sickle Cell Disease. This designation supports the development of therapies for rare diseases and may provide marketing exclusivity upon approval. The press release highlights the potential of Desidustat to increase hemoglobin and red blood cell counts, addressing an urgent medical need. Dr. Sharvil Patel emphasized the importance of this designation in developing effective treatments for Sickle Cell Disease.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 06, 2026, titled "Zydus receives USFDA Orphan Drug Designation (ODD) for Desidustat for the treatment of Sickle Cell Disease".

Zydus Lifesciences Limited on 6ix

In the deck

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases